Prof. Jordi Rodon, MD [7505]

What is the role of NGS in the current environment of precision-focused cancer therapy? (Spanish) Video

What is the role of NGS in the current environment of precision-focused cancer therapy? (Spanish)

What is the role of NGS in the current environment of precision-focused cancer therapy? (Spanish)
Prof. Jordi Rodon, MD

Prof. Jordi Rodon, MD

Does NGS report molecular rearrangements as an all or none phenomenon? What is the importance of subclones as far as interpretation of genomic profiles of tumors? (Spanish) Video

Does NGS report molecular rearrangements as an all or none phenomenon? What is the importance of subclones as far as interpretation of genomic profiles of tumors? (Spanish)

Does NGS report molecular rearrangements as an all or none phenomenon? What is the importance of subclones as far as interpretation of genomic profiles of tumors? (Spanish)
Prof. Jordi Rodon, MD

Prof. Jordi Rodon, MD

What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE? (Spanish) Video

What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE? (Spanish)

What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE? (Spanish)
Prof. Jordi Rodon, MD

Prof. Jordi Rodon, MD

What information do genomic profiling assays that employ NGS -- including FoundationOne -- provide on a tumor- and patient-specific basis? Coding sequence for cancer-related genes and exons? How many introns from how many genes? (Spanish) Video

What information do genomic profiling assays that employ NGS -- including FoundationOne -- provide on a tumor- and patient-specific basis? Coding sequence for cancer-related genes and exons? How many introns from how many genes? (Spanish)

What precise information do commercially-available genomic profiling assays that employ NGS — including FoundationOne — provide on a tumor- and patient-specific basis? Coding sequence for how many cancer-related genes and exons? How many ...
Prof. Jordi Rodon, MD

Prof. Jordi Rodon, MD

What kind of information is reported on the FoundationOne or other NGS genomic profiling tests? What specific alterations and rearrangements are reported, how does one interpret the report? (Spanish) Video

What kind of information is reported on the FoundationOne or other NGS genomic profiling tests? What specific alterations and rearrangements are reported, how does one interpret the report? (Spanish)

What kind of information is reported on the FoundationOne or other NGS genomic profiling tests? What kind of specific alterations and rearrangements are reported, how does one interpret the report, and what kind of recommendations does ...
Prof. Jordi Rodon, MD

Prof. Jordi Rodon, MD

How is NGS sequencing used in the setting of basket trials designed to evaluate the role of genomic alterations and matched therapies to improve outcomes in patients with cancer? (Spanish) Video

How is NGS sequencing used in the setting of basket trials designed to evaluate the role of genomic alterations and matched therapies to improve outcomes in patients with cancer? (Spanish)

How is NGS sequencing used in the setting of basket trials designed to evaluate the role of genomic alterations and matched therapies to improve outcomes in patients with cancer? (Spanish)
Prof. Jordi Rodon, MD

Prof. Jordi Rodon, MD

Can an FFPE sample analyzed by hybrid capture NGS indicate the presence of more than one actionable genomic alteration? Which alteration should drive initial choice of a targeted anti-tumor agent? (Spanish) Video

Can an FFPE sample analyzed by hybrid capture NGS indicate the presence of more than one actionable genomic alteration? Which alteration should drive initial choice of a targeted anti-tumor agent? (Spanish)

Can an FFPE sample analyzed by hybrid capture NGS indicate the presence of more than one actionable genomic alteration? If so, which alteration should drive the initial choice of a targeted anti?tumor agent? (Spanish)
Prof. Jordi Rodon, MD

Prof. Jordi Rodon, MD